FDA Expands Indication of Lorlatinib for ALK-Positive Non–Small Cell Lung Cancer

Article

The FDA has approved a supplemental new drug application for lorlatinib (Lorbrena) to expand the indication to include the frontline treatment of patients with ALK-positive non–small cell lung cancer.

The FDA has approved a supplemental new drug application for lorlatinib (Lorbrena) to expand the indication to include the frontline treatment of patients with ALK-positive non–small cell lung cancer (NSCLC) as detected by an FDA-approved test. The regulatory based on the data from the pivotal phase 3 CROWN trial (NCT03052608), where lorlatinib resulted in a 72% reduction in risk of progression or death compared with crizotinib (Xalkori) in treatment-naïve patients (HR 0.28; 95% CI, 0.19-0.41; <.0001) per blinded independent central review (BICR) assessment.

“For more than a decade, Pfizer has been a pioneer in delivering biomarker-driven therapies and addressing the diverse and evolving needs of people with non-small cell lung cancer,” Andy Schmeltz, Global President of Pfizer Oncology, stated in a press release. “[Lorlatinib] has been a transformative medicine for people with ALK-positive advanced NSCLC, and this FDA approval in the first-line setting means that we can now extend hope to even more people.”

Central nervous system (CNS) involvement was evaluated in all study participants. Seventeen patients in the investigative arm and 13 in the control arm had measurable brain metastases per baseline brain imaging. Results from a prespecified exploratory analysis demonstrated that among these patients, the intracranial objective response rate per BICR assessment was 82% (95% CI, 57-96) in the lorlatinib arm vs 23% (95% CI, 5-54) in the crizotinib arm. Moreover, the intracranial duration of response was 12 months or longer in 79% of those who received lorlatinib (n = 11) vs 0% in those given crizotinib.

Click to continue reading on OncLive.

Related Videos
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
Image credit: New Africa | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Pharmacist holding medicine box and capsule pack in pharmacy drugstore. -- Image credit: I Viewfinder | stock.adobe.com
Image credit: Goffkein | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.